Marc A. Rubenstein, a partner in the life sciences practice group, focuses on representing clients in the biotechnology, medical device and pharmaceutical industries in a wide variety of transactions, including license and collaboration agreements, public and private securities offerings and mergers and acquisitions.
He has extensive experience representing life sciences clients in structuring and negotiating collaborative research, development and licensing arrangements. In these transactions, Marc has represented both licensors and licensees, and has negotiated early and late stage product agreements and platform and drug discovery deals.
In addition, he has broad experience negotiating supply and manufacturing agreements, distribution and co-promotion agreements, university license agreements, sponsored research agreements and other commercial agreements that arise regularly in the life sciences industry.
Marc regularly represents publicly traded life sciences companies in securities matters, including IPOs, PIPEs, standby equity lines, at-the-market offerings and other types of financings, as well as advising these companies in ongoing reporting matters.
He also represents venture-backed life sciences companies in financings and ongoing matters, and has extensive experience advising public and private life sciences companies in mergers and acquisitions, including tender offers, mergers and asset acquisitions and sales.
- JD, cum laude , Cornell Law School, 1989; Note Editor, Cornell International Law Journal, Editor, 1989 Symposium Issue, Harvard Journal of Law and Public Policy
- BA, Cornell University, 1986
ADMISSIONS : Massachusetts
PROFESSIONAL & CIVIC ACTIVITIES :
- Board of Overseers of the Boston Museum of Science
- Board of Trustees and Executive Committee of Jewish Big Brothers Big Sisters of Greater Boston
- Head’s Council of the Loomis Chaffee School
- Represented Mersana Therapeutics in its $75 million initial public offering.
- Represented Vertex Pharmaceuticals in its $230 million licensing agreement with Merck KGaA, in which Merck obtained the worldwide development and commercialization rights of four research and development programs from Vertex that represent novel approaches to the treatment of cancer.
- Represented Vertex Pharmaceuticals in its $2.1 billion strategic research and collaboration agreement with CRISPR Therapeutics focused on the use of CRISPR’s gene editing technology, known as CRISPR-Cas9, to discover and develop potential new treatments aimed at the underlying genetic causes of human disease for a number of selected targets.
- Represented Aegerion Pharmaceuticals in its $325 million acquisition of AstraZeneca’s Myalept, also known as metreleption, the only U.S. approved orphan product designed to treat complications of leptin deficiency in patients with generalized lipodystrophy.
- Represented Acceleron Pharma in its initial public offering and concurrent private placement by Celgene with aggregate proceeds of $94 million. Also represented Acceleron in multiple follow-on public offerings.
- Represented Synageva BioPharma in its reverse merger with Trimeris and its two follow on offerings in 2012, with total proceeds of over $200 million.
- Represented Ironwood Pharmaceuticals in developing and implementing its worldwide licensing strategy for linaclotide, including licensing linaclotide to Forest Laboratories, Laboratorios Almirall, Astellas Pharma and AtraZeneca with aggregate upfront payments of $165 million.
- Represented Beam Therapeutics in its Series A financing that included Circle Ventures and F-Prime Capital and in connection with its licenses from Editas Medicine and The Broad Institute.
Rate : $$$